During 2018, 23,739 MSM were tested at the pharyngeal site for gonorrhea and/or chlamydia (23,695 for gonorrhea and 21,767 for chlamydia) in eight of the 10 SSuN jurisdictions where data was available. Pharyngeal testing varied between 52.2%–86.5% for gonorrhea and between 68.2–76.6% for chlamydia. Among MSM who were tested at the pharyngeal site for gonorrhea, the median positivity was 12.9% (range: 8.0%–19.8%). In contrast, MSM tested at the pharyngeal site for chlamydia was 2.7% (range: 2.0%–3.1%). Pharyngeal chlamydia testing data was not available for Minnesota.